{
    "nct_id": "NCT06524635",
    "official_title": "A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis",
    "inclusion_criteria": "* Sub-Study 1 hidradenitis suppurativa (HS):\n* Participants with a diagnosis of moderate-to-severe HS for at least 6 months prior to Baseline as determined by the investigator\n* Participants naïve to biologic treatment for HS or must have a prior inadequate response or loss of response to anti-TNF therapy for HS (>= 12 weeks of therapy).\n* Sub-Study 2 atopic dermatitis (AD):\n* Participants with a diagnosis of moderate-to-severe AD with onset of symptoms at least 1 year prior to Baseline.\n* Participants naïve to biologic treatment for AD or must have a prior inadequate response or loss of response to dupilumab for AD (defined as >= 8 weeks of therapy with dupilumab).\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* History of any malignancy within the last 5 years except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.\n* History of active skin disease (other than HS for Sub-Study 1 or AD for Sub-Study 2) that could interfere with the assessment of HS (for Sub-Study 1) or AD (for Sub-Study 2), including skin infections (e.g., bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline.",
    "miscellaneous_criteria": ""
}